193 related articles for article (PubMed ID: 36632565)
1. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R
Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
[TBL] [Abstract][Full Text] [Related]
3. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
5. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
[TBL] [Abstract][Full Text] [Related]
6. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
Mustafa N; Nee AHF; Chooi JY; Toh SHM; Chung TH; Selvarajan V; Fan S; Ng SB; Poon M; Chan E; Lee J; Chee YL; Jeyasekharan AD; Zhou L; Yang J; Chng WJ
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215687
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
9. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.
Buteyn NJ; Fatehchand K; Santhanam R; Fang H; Dettorre GM; Gautam S; Harrington BK; Henderson SE; Merchand-Reyes G; Mo X; Benson DM; Carson WE; Vasu S; Byrd JC; Butchar JP; Tridandapani S
Int Immunol; 2018 Jul; 30(8):375-383. PubMed ID: 29868798
[TBL] [Abstract][Full Text] [Related]
12. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N; Arndt C; Petersen J; Lustig M; Rösner T; Klausz K; Kellner C; Bultmann M; Bastian L; Vogiatzi F; Leusen JHW; Burger R; Schewe DM; Peipp M; Valerius T
Front Immunol; 2022; 13():949140. PubMed ID: 36052078
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.
Brennan K; Iversen KF; Blanco-Fernández A; Lund T; Plesner T; Mc Gee MM
Cells; 2022 Oct; 11(21):. PubMed ID: 36359760
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
[TBL] [Abstract][Full Text] [Related]
15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
16. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
18.
Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
[TBL] [Abstract][Full Text] [Related]
20. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab.
Terasaki Y; Okumura H; Saito K; Sato Y; Yoshino T; Ichinohasama R; Ishida Y
Intern Med; 2008; 47(24):2175-8. PubMed ID: 19075546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
